Hypersensitivity to antineoplastic agents

Current Pharmaceutical Design

Volumn 14, Issue 27, 2008, Pages 2892-2901

  Castells, M C ^a  

^a One Jimmy Fund Way ^*  (United States)

Author keywords

Adverse drug reactions; Anaphylaxis; Chemotherapy agents; Hypersensitivity reactions; Monoclonal antibodies; Rapid desensitization

Indexed keywords

ADALIMUMAB; ADRENALIN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE; CARBOPLATIN; CISPLATIN; CREMOPHOR; DOCETAXEL; DOXORUBICIN; DRUG VEHICLE; ETANERCEPT; HISTAMINE; IMMUNOGLOBULIN E; INFLIXIMAB; LEUKOTRIENE; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PROSTAGLANDIN; PROTEINASE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TRYPTASE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APNEA; BACKACHE; BLOATING; BREAST CANCER; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHILL; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTINUOUS INFUSION; COUGHING; CROSS LINKING; CYANOSIS; DESENSITIZATION; DIARRHEA; DISORIENTATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIZATION; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA MULTIFORME; EYE TUMOR; FATALITY; FATTY ACID DESATURATION; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GLIOMA; HALLUCINATION; HEARING DISORDER; HEART PALPITATION; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INTENSIVE CARE UNIT; LABORATORY DIAGNOSIS; MACULOPAPULAR RASH; MULTIPLE CYCLE TREATMENT; MUSCLE DISEASE; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NOSE CONGESTION; OVARY CANCER; PAIN; PARESTHESIA; PHARMACODYNAMICS; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; RESUSCITATION; REVIEW; SHOCK; SIDE EFFECT; SKIN DISEASE; SKIN MANIFESTATION; SKIN TEST; SNEEZING; SOLID TUMOR; STEVENS JOHNSON SYNDROME; SWELLING; SYNCOPE; SYSTEMIC DISEASE; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROAT TIGHTNESS; TOXIC EPIDERMAL NECROLYSIS; TYPE 1 HYPERSENSITIVITY REACTION; URTICARIA; VISUAL DISORDER; WEAKNESS; WHEEZING;

ANAPHYLAXIS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG HYPERSENSITIVITY; HUMANS; NEOPLASMS;

EID: 65949105932     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786369803     Document Type: Review

References (47)

1. Weiss RB, Bruno S. Hypersensitivity reactions to cancer chemotherapeutic agents. Ann Intern Med 1981; 94: 66-72.
2. Vervloet D, Durham S. Adverse reactions to drugs. BMJ 1998; 316: 1511-4.
3. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53: 121-2.
4. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med 1985; 312: 1229-32.
5. Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol 1982; 69: 500-8.
6. Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19: 3126-9.
7. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141.
8. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: Experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 2000; 18: 102-5.
9. Goldberg A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996; 98: 841-3.
10. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 2005; 94: 575-80.
11. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: A new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96: 824-9.
12. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: A 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95: 370-6.
13. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99: 393-9.
14. Solensky R. Drug hypersensitivity. Med Clin North Am 2006; 90: 233-60.
15. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-6.
16. Sampson HA, Muñoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA, et al. Symposium on the Definition and Management of Anaphylaxis: Summary report. J Allergy Clin Immunol 2005; 115: 584-91
17. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21: 4611-4.
18. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002; 23: 205-8.
19. Macglashan D, Miura K. Loss of syk kinase during IgE-mediated stimulation of human basophils. J Allergy Clin Immunol 2004; 114: 1317-24.
20. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM. Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol 1999; 104: 279-84.
21. Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11: 885-90.
22. Fishman A, Gold T, Goldberg A, Confino-Cohen R, Beyth Y, Menczer J, et al. Effective desensitization protocol to paclitaxel following hypersensitivity reaction. Int J Gynecol Cancer 1999; 9: 156-9.
23. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol 1999; 125: 427-9.
24. Markman M, Hsieh F, Zanotti K, Webster K, Peterson G, Kulp B, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130: 25-8.
25. Grosen E, Siitari E, Larrison E, Tiggelaar C, Roecker E. Paclitaxel hypersensitivity reactions related to bee-sting allergy. Lancet 2000; 355: 288-9.
26. Kook H, Kim KM, Choi SH, Choi BS, Kim HJ, Chung SY, et al. Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: Successful rechallenge after desensitization. Bone Marrow Transplant 1998; 21: 727-9.
27. Sims-McCallum RP. Outpatient carboplatin desensitization in a pediatric patient with bilateral optic glioma. Ann Pharmacother 2000; 34: 477-8
28. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26: 105-10.
29. Morgan M, Bowers DC, Gruchalla RS, Khan DA. Safety and efficacy of repeated monthly carboplatin desensitization. J Allergy Clin Immunol 2004; 114: 974-5.
30. Ottaiano A, Tambaro R, Greggi S, Prato R, Di Maio M, Esposito G, et al. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 2003; 23: 3465-8.
31. Goldberg A, Altaras MM, Mekori YA, Beyth Y, Confino-Cohen R. Anaphylaxis to cisplatin: Diagnosis and value of pretreatment in prevention of recurrent allergic reactions. Ann Allergy 1994; 73: 271-2.
32. Gammon D, Bhargava P, McCormick MJ. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. Oncologist 2004; 9: 546-9.
33. Mis L, Fernando NH, Hurwitz HI, Morse MA. Successful desensitization to oxaliplatin. Ann Pharmacother 2005; 39: 966-9.
34. Ogle SK, Rose MM, Wildes CT. Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1 and hypersensitivity reactions in an outpatient oncology clinic. J Pediatr Oncol Nurs 2002; 19: 122-6.
35. Bonno M, Kawasaki H, Hori H, Umemoto M, Komada Y, Sakurai M. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 1998; 101: 571-2.
36. Stone HD Jr, DiPiro C, Davis PC, Meyer CF, Wray BB. Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol 1998; 101: 429-31.
37. Guo Y. Desensitization therapy of acute lymphocytic leukemia with injection of L-asparaginase (Report of 5 cases). Zhonghua Er Ke Za Zhi 2005; 43: 309-10.
38. Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994; 47: 223-58.
39. Rigatos SK, Tsavdaridis D, Athanasiadis A, Stathopoulos JG, Stathopoulos GP. Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: A phase II study. Oncol Rep 2003; 10: 1817-9.
40. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995; 13: 914-20.
41. Tada K, Ito Y, Hatake K, Okudaira T, Watanabe J, Arakawa M, et al. Severe infusion reaction induced by trastuzumab: A case report. Breast Cancer 2003; 10: 167-9.
42. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angiedema-like skin reactions in a patient treated with adalimumab. Clin Rheumatol 2007; 26: 787-8.
43. Chávez-López MA, Delgado-Villafaña J, Gallaga A, Huerta-Yáñez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol 2005; 33: 291-2.
44. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004; 16: 627-30.
45. Docampo R, Moreno SN. The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr Pharm Des 2008; 14(9): 882-8.
46. Koh Y, Yap CW, Li SC. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system. Int J Med Inform 2008; 77(6): 421-30.
47. Spankuch B, Strebhardt K. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Curr Pharm Des 2008; 14(11): 1098-112.